The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.
Question for Tim regarding FDA approval of GSK drugs
Do you know whether those who are BRAF 600E positive and have had Zelboraf in the past are eligible for the GSK BRAF and/or MEK inhibitor? I read the GSK press release which states that the BRAF inhibitor (Tafinlar) is not indicated for use for those who have BRAF-wildtype melanoma. For the MEK inhibitor (Mekinist), it says the same thing and also that it is "not indicated for the treatment of patients who have received a prior BRAF therapy." If that's the case, it seems that everyone who has had Zelboraf cannot have the MEK inhibitor.
The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.
The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.